Dovitinib lactate is under clinical development by Allarity Therapeutics and currently in Phase II for Breast Cancer. According to GlobalData, Phase II drugs for Breast Cancer have a 34% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Dovitinib lactate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Dovitinib lactate overview
Dovitinib lactate (TKI258, CHIR-258) is under development for the treatment of breast cancer, hepatocellular carcinoma, endometrial cancer, gastrointestinal stromal tumor (GIST), osteosarcoma and metastatic renal cell carcinoma. It inhibits PDGFR beta, CSF 1R, KIT, FLT3, VEGFR, TrkA, RET and FGFRs. Inhibition of tyrosine kinase results in the induction of endothelial cell apoptosis, a reduction in tumor vasculature, anti-angiogenesis and the inhibition of tumor cell proliferation and migration.
It was under development by Novartis for the treatment of solid tumors such as colorectal cancer, metastatic HER2 negative breast cancer, advanced scirrhous gastric carcinoma, bladder cancer, metastatic adenoid cystic carcinoma, paragangliomas, pancreatic endocrine tumor, adrenocortical carcinoma, gastric cancer, glioblastoma, non-small cell lung cancer, Von Hippel-Lindau syndrome, transitional cell carcinoma (urothelial cell carcinoma), advanced hepatocellular carcinoma, adenoid cystic carcinoma of the salivary gland, pancreatic cancer, relapsed or refractory multiple myeloma, metastatic melanoma and acute myelocytic leukemia.
Allarity Therapeutics overview
Allarity Therapeutics (Allarity) is a precision medicine company that develops drugs for cancer. The company is investigating Dovitinib, a pan-tyrosine kinase inhibitor targeting RCC (renal cell cancer), gastrointestinal stromal tumor (GIST), liver, metastatic breast, and endometrial cancer; and Stenoparib, a dual PARP and Tankyrase inhibitor against ovarian cancer. It is also evaluating Ixempra (ixabepilone), a cell-cycle specific antimicrotubule agent; and LiPlaCis, a target controlled liposome formulation to treat metastatic breast cancer; and 2X-111 targeting glioblastoma multiform (GBM) and brain metastases of breast cancer (mBC). Allarity utilizes its proprietary drug response predictor (DRP) diagnostic platform technology that models human tumor biology and predicts cancer patient response. The company has operational presence in Hoersholm, Denmark. Allarity is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of Dovitinib lactate’s drug-specific PTSR and LoA scores, buy the report here.